Ovarian Cancer Includes More Than One Kind of Malignancy
Ovarian cancer isn’t a single disease, but rather a number of different malignancies, and better understanding is needed to improve prevention and treatment according to a U.S. panel.
Ovarian cancer isn’t a single disease, but rather a number of different malignancies, and better understanding is needed to improve prevention and treatment according to a U.S. panel.
Malignant melanoma was differentiated from benign skin lesions with high accuracy in a pivotal clinical utility study of the Myriad myPath Melanoma test.
A combination of blood proteins was able to differentiate between benign lung nodules and early-stage lung cancer with 90% probability, thereby providing a diagnostic tool to avoid invasive biopsy on benign nodules.
Malignant mesothelioma is a rare asbestos-associated malignancy with limited therapeutic options. But recent research has concluded that Eprin (EPH) B2 seems to play an important role in malignant pleural mesothelioma cell lines and tumors.
Melanoma tumors create conditions that attract immunoglobulin G4 (IgG4), the B-cell antibody class least effective in activating immune response.
Inhibiting one protein eliminated metastasis of melanoma in lab studies, a finding that could lead to targeted therapies for a range of cancers.
Excessive levels of interleukin-15 initiate large granular lymphocyte (LGL) leukemia, but also represent a promising therapeutic target.
For ovarian cancer and perhaps other cancer types, cell stiffness may be a useful biomarker to measure relative metastatic potential.
Assessing how water moves through breast tissue may reduce false-positive findings among women undergoing dynamic contrast-enhanced MRI.
The quality of breast cancer surgery improved when percutaneous needle biopsy was performed preoperatively.